Stockreport

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Addi [Read more]